Agilent Announces Thought Leader Award to Gerhardt Attard at University College London (UCL)
02 Agosto 2022 - 9:07AM
Business Wire
Award recognizes transformative prostate cancer clinical
research using novel liquid biopsy technologies
Agilent Technologies Inc. (NYSE: A) today announced that
Professor Gerhardt Attard has been selected to receive a
prestigious Agilent Thought Leader Award. Prof Attard is a John
Black Charitable Foundation Endowed Chair in Urological Cancer
Research at University College London (UCL). Professor Attard is
prominent for his innovative research and clinical trials using
cutting-edge liquid biopsy technologies to identify biomarkers to
monitor drug response and cancer progression in patients with
advanced prostate cancer. The technique is non-invasive and,
therefore, ideal for tracking tumor response to therapy and the
evolution of cancer mutation.
Professor Attard is an influential oncology clinician-scientist
whose work has enabled the application of modern genomics clinical
solutions, such as liquid biopsy, to create the next generation of
diagnostics and prognostic tools in the fight against cancer.
Professor Attard’s research supported by this award will generate
important data using relevant samples from clinical trials to
identify and test changes in the circulating tumor DNA methylome
that could be used as biomarkers for cancer progression and
resistance to available therapies.
“The Agilent Thought Leader Award will support my group’s work
interrogating tumor epigenetic information in plasma DNA. As
translational researchers, one of our key remits is to transition
new discoveries into clinically-implemented tests,” said Professor
Attard. “I am thrilled to receive this award. It is a great honor
and important opportunity for my team and our collaborators to work
with some of the industry leaders in the diagnostics field.”
“My group primarily studies blood collected from men with
advanced prostate cancer, but I expect our findings to have
relevance to and support new tests for other cancer types,”
Professor Attard added. “I am confident that this partnership will
accelerate our delivery of diagnostics that will provide cancer
physicians more precise information to tailor treatment paradigms
and improve patient outcomes.”
“Agilent continues to invest in research on the important
segment markets we serve,” said Ronda Allen, head of R&D,
Assays and Reagents, Diagnostics and Genomics Group at Agilent and
executive sponsor of the award. “The important work conducted
through this award will support scientific developments in the
cancer genomics space and we believe Professor Attard will be a
brilliant asset in that endeavor.”
“Philanthropic gifts like the Agilent Thought Leader Award are
crucial to enabling UCL’s world-leading scientists to make
life-saving discoveries, that could alter the clinical landscape
for advanced prostate cancer patients and those with other
cancers,” said Angharad Milenkovic, vice-president of Advancement
at UCL. “We’re grateful to our philanthropic partners at Agilent,
who share our vision for improving cancer diagnosis and treatment,
and for their generous funding of Professor Attard’s research.”
Professor Attard holds an advanced Cancer Research UK Clinician
Scientist award and is Team Leader of the Treatment Resistance
Group at the UCL Cancer Institute.
The Agilent Thought Leader Award program promotes fundamental
scientific advances by contributing financial support, products,
and expertise to the research of influential thought leaders in the
life sciences, diagnostics, and chemical analysis space. To learn
more, visit the Agilent Thought Leader Award website.
About Agilent Technologies
Agilent Technologies Inc. (NYSE: A) is a global leader in the
life sciences, diagnostics, and applied chemical markets,
delivering insight and innovation that advance the quality of life.
Agilent’s full range of solutions includes instruments, software,
services, and expertise that provide trusted answers to our
customers' most challenging questions. The company generated
revenue of $6.32 billion in fiscal 2021 and employs 17,000 people
worldwide. Information about Agilent is available at
www.agilent.com. To receive the latest
Agilent news, please subscribe to the Agilent Newsroom. Follow
Agilent on LinkedIn, Twitter, and Facebook.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220802005284/en/
Naomi Goumillout Agilent Technologies +1.781.266.2819
naomi.goumillout@agilent.com
Agilent Technologies (NYSE:A)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024
Agilent Technologies (NYSE:A)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024